

# Resource Summary Report

Generated by [dkNET](#) on Sep 7, 2026

## SW48

RRID:CVCL\_1724

Type: Cell Line

### Proper Citation

RRID:CVCL\_1724

### Cell Line Information

**URL:** [https://web.expasy.org/cellosaurus/CVCL\\_1724](https://web.expasy.org/cellosaurus/CVCL_1724)

**Proper Citation:** RRID:CVCL\_1724

**Description:** Cell line SW48 is a Cancer cell line with a species of origin Homo sapiens (Human)

**Sex:** Female

**Disease:** Colon adenocarcinoma

**Defining Citation:** [PMID:327080](#), [PMID:793708](#), [PMID:833871](#), [PMID:924690](#), [PMID:1000501](#), [PMID:3518877](#), [PMID:6220172](#), [PMID:6652615](#), [PMID:7104989](#), [PMID:7459858](#), [PMID:7651727](#), [PMID:8197130](#), [PMID:8422623](#), [PMID:8464898](#), [PMID:9000572](#), [PMID:9294210](#), [PMID:9515795](#), [PMID:10612807](#), [PMID:10737795](#), [PMID:11314036](#), [PMID:11526487](#), [PMID:12615714](#), [PMID:16418264](#), [PMID:18258742](#), [PMID:19927377](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:20570890](#), [PMID:20606684](#), [PMID:22460905](#), [PMID:24042735](#), [PMID:24755471](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25926053](#), [PMID:25944804](#), [PMID:25984343](#), [PMID:26537799](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:28683746](#), [PMID:28854368](#), [PMID:29101300](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:35839778](#)

**Comments:** Population: Caucasian., From: Scott and White Clinic; Temple; USA., Part of: MD Anderson Cell Lines Project., Part of: EGFR genetic alteration cell panel (ATCC TCP-1027)., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

**Category:** Cancer cell line

**Organism:** Homo sapiens (Human)

**Name:** SW48

**Synonyms:** SW-48, SW 48

**Cross References:** BTO:BTO\_0001535, CLO:CLO\_0009216, EFO:EFO\_0002367, CLDB:cl4971, AddexBio:C0009014/373, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CCL-231, BCRC:60311, BioGRID\_ORCS\_Cell\_line:362, BioSample:SAMN03470827, BioSample:SAMN03471477, BioSample:SAMN10988325, cancercellines:CVCL\_1724, Cell\_Model\_Passport:SIDM00837, ChEMBL-Cells:ChEMBL3307292, ChEMBL-Targets:ChEMBL614055, CLS:305235, ColonAtlas:SW48, Cosmic:687544, Cosmic:711258, Cosmic:870450, Cosmic:873705, Cosmic:876645, Cosmic:876707, Cosmic:887225, Cosmic:889527, Cosmic:909751, Cosmic:948122, Cosmic:948855, Cosmic:986000, Cosmic:995399, Cosmic:1043828, Cosmic:1057753, Cosmic:1122330, Cosmic:1132563, Cosmic:1132688, Cosmic:1175846, Cosmic:1184089, Cosmic:1184332, Cosmic:1374624, Cosmic:1466821, Cosmic:1479633, Cosmic:1552177, Cosmic:1571771, Cosmic:1609488, Cosmic:1676725, Cosmic:1708409, Cosmic:1805268, Cosmic:1995653, Cosmic:2036657, Cosmic:2052594, Cosmic:2302017, Cosmic:2389571, Cosmic:2667883, Cosmic:2667978, Cosmic:2668254, Cosmic:2727480, Cosmic:2760064, Cosmic:2787543, Cosmic:2820498, Cosmic-CLP:909751, DepMap:ACH-000958, ECACC:89012702, EGA:EGAS00001000610, EGA:EGAS00001000978, EGA:EGAS00001002554, GDSC:909751, GEO:GSM513924, GEO:GSM514311, GEO:GSM741252, GEO:GSM827355, GEO:GSM844713, GEO:GSM887675, GEO:GSM888767, GEO:GSM1346890, GEO:GSM1374925, GEO:GSM1374926, GEO:GSM1374927, GEO:GSM1448165, GEO:GSM1670507, GEO:GSM2550015, IARC\_TP53:4556, IARC\_TP53:21768, ICLC:HTL99020, IGRhCellID:SW48, LiGeA:CCLE\_034, LINCS\_LDP:LCL-1186, Lonza:86, MetaboLights:MTBLS227, NCBI\_Iran:C480, PharmacDB:SW48\_1538\_2019, PRIDE:PXD005235, PRIDE:PXD005354, PRIDE:PXD005355, PRIDE:PXD030304, Progenetix:CVCL\_1724, PubChem\_Cell\_line:CVCL\_1724, SKY/M-FISH/CGH:2838, Ubigen:YC-C126, Wikidata:Q54971115

**ID:** CVCL\_1724

**Record Creation Time:** 20220427T221615+0000

**Record Last Update:** 20260905T182522+0000

---

## Ratings and Alerts

No rating or validation information has been found for SW48.

No alerts have been found for SW48.

---

## Data and Source Information

**Source:** [Cellosaurus](#)

---

## Usage and Citation Metrics

We found 202 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [dkNET](#) .

Li L, et al. (2026) Ubiquitination-directed cytosolic DNA degradation governs cGAS-STING-mediated immune response to DNA damage. *Cancer cell*.

Zhan W, et al. (2026) Cathepsin-D-mediated MHC class I degradation contributes to immune evasion in colorectal cancer. *Cell reports. Medicine*, 102534.

Gao J, et al. (2026) AURKA-mediated destabilization of SAPS3 drives ferroptosis evasion via 7-dehydrocholesterol biosynthesis in colorectal cancer. *Cell death & disease*, 17(1).

Liu A, et al. (2026) Soluble Uric Acid Drives CD8+ T-cell Exhaustion by Inducing KSR1-Mediated MAPK Hyperactivation. *Cancer research*, 86(14), 3459.

Baars B, et al. (2026) RAS Mutation-Specific Responses to Paralog- and State-Selective RAS Inhibitors. *Molecular cancer research : MCR*, 24(1), 60.

Yue Z, et al. (2026) Subcellular Redistribution of Endomembrane GPR15 Promotes NAD<sup>+</sup>-Mediated Metabolic Reprogramming and Boosts 5-FU Chemosensitivity in Colorectal Cancer. *Cancer research*, 86(9), 2253.

Renner F, et al. (2026) Mosperafenib, a Novel Paradox-Breaker BRAF Inhibitor with Potent Preclinical Activity in BRAF-Mutated Colorectal Cancer. *Molecular cancer therapeutics*, 25(4), 599.

Tao G, et al. (2026) Radiation-induced MYB reduction unleashes TIM-3 expression in NK cells to attenuate antitumor immunity in colorectal cancer. *Journal of translational medicine*, 24(1).

Zhu G, et al. (2026) Accumulated sotorasib-bound KRASG12C reactivates the MAPK pathway and drives sotorasib resistance via the DHX9-RAC1-PAK1 axis. *Cell reports*, 45(5), 117338.

Han Y, et al. (2025) Identifying an optimal perturbation to induce a desired cell state by generative deep learning. *Cell systems*, 101405.

Santiappillai NT, et al. (2025) Pathway metabolite ratios reveal distinctive glutamine metabolism in a subset of proliferating cells. *Molecular systems biology*, 21(8), 983.

Alam Z, et al. (2025) Fosl1 is a transcriptional effector of BRAF V600E-driven intestinal tumorigenesis. *iScience*, 28(11), 113875.

Chen MY, et al. (2025) BAG2 releases SAMD4B upon sensing of arginine deficiency to promote tumor cell survival. *Molecular cell*, 85(13), 2581.

Zhang C, et al. (2025) Targeting WEE1 in ARID1A/TP53 Concurrent Mutant Colorectal Cancer by Exploiting R-Loop Accumulation and DNA Repair Deficiencies. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, e12074.

Castro J, et al. (2025) A Potent, Selective, Small-Molecule Inhibitor of DHX9 Abrogates Proliferation of Microsatellite Instable Cancers with Deficient Mismatch Repair. *Cancer research*, 85(4), 758.

Chau TL, et al. (2025) Purinergic ecto-enzyme CD73 is a context-dependent tumor suppressor in colorectal cancer. *The Journal of biological chemistry*, 301(12), 110864.

Feng Z, et al. (2025) Nanobody-Directed CEA-Targeting CAR T Cells Eliminate Gastrointestinal Cancer Xenografts. *Cancer immunology research*, 13(8), 1160.

Baglamis S, et al. (2025) Clonal dispersal is associated with tumor heterogeneity and poor prognosis in colorectal cancer. *iScience*, 28(5), 112403.

Yokoi R, et al. (2025) Single-molecule imaging quantifies oncogenic KRAS dynamics for enhanced accuracy of therapeutic efficacy assessment. *iScience*, 28(9), 113374.

Zerbib J, et al. (2024) Human aneuploid cells depend on the RAF/MEK/ERK pathway for overcoming increased DNA damage. *Nature communications*, 15(1), 7772.